ATE484497T1 - Sulfonylbenzimidazolderivate - Google Patents
SulfonylbenzimidazolderivateInfo
- Publication number
- ATE484497T1 ATE484497T1 AT07705657T AT07705657T ATE484497T1 AT E484497 T1 ATE484497 T1 AT E484497T1 AT 07705657 T AT07705657 T AT 07705657T AT 07705657 T AT07705657 T AT 07705657T AT E484497 T1 ATE484497 T1 AT E484497T1
- Authority
- AT
- Austria
- Prior art keywords
- pain
- disease
- compounds
- ischemia
- fibromyalgia
- Prior art date
Links
- IYUBCLHILARKQB-UHFFFAOYSA-N 2-sulfonylbenzimidazole Chemical class C1=CC=CC2=NC(=S(=O)=O)N=C21 IYUBCLHILARKQB-UHFFFAOYSA-N 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 6
- 201000006474 Brain Ischemia Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 3
- 208000008035 Back Pain Diseases 0.000 abstract 2
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 201000001119 neuropathy Diseases 0.000 abstract 2
- 230000007823 neuropathy Effects 0.000 abstract 2
- 208000000884 Airway Obstruction Diseases 0.000 abstract 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000008930 Low Back Pain Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 208000001294 Nociceptive Pain Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063897 Renal ischaemia Diseases 0.000 abstract 1
- 208000036284 Rhinitis seasonal Diseases 0.000 abstract 1
- 208000008765 Sciatica Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000005962 mycosis fungoides Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000003349 osteoarthritic effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77977606P | 2006-03-06 | 2006-03-06 | |
| US79535406P | 2006-04-26 | 2006-04-26 | |
| PCT/IB2007/000474 WO2007102059A1 (en) | 2006-03-06 | 2007-02-23 | Sulfonyl benzimidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE484497T1 true ATE484497T1 (de) | 2010-10-15 |
Family
ID=38179500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07705657T ATE484497T1 (de) | 2006-03-06 | 2007-02-23 | Sulfonylbenzimidazolderivate |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7700618B2 (de) |
| EP (1) | EP1994011B1 (de) |
| JP (1) | JP2009536918A (de) |
| AT (1) | ATE484497T1 (de) |
| CA (1) | CA2645257C (de) |
| DE (1) | DE602007009807D1 (de) |
| WO (1) | WO2007102059A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935715B2 (en) | 2006-07-28 | 2011-05-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| JP5030114B2 (ja) | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体をモジュレートする化合物 |
| WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| EP2217565B1 (de) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Cb2 rezeptor-modulierende verbindungen |
| US20100273831A1 (en) * | 2007-12-17 | 2010-10-28 | Henricus Jacobus Maria Gijsen | Fluoro alkyl substituted benzimidazole cannabinoid agonists |
| CA2730037A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
| EP2342199B1 (de) | 2008-09-25 | 2014-02-26 | Boehringer Ingelheim International GmbH | Sulfonylverbindungen als selektive CB2 Rezeptor Modulatoren |
| EP2379533A4 (de) * | 2009-01-22 | 2012-07-04 | Raqualia Pharma Inc | N-substituierte gesättigte heterozyklische sulfonverbindungen mit cb2-rezeptor-agonistenwirkung |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| ES2628219T3 (es) * | 2009-05-19 | 2017-08-02 | Vivia Biotech S.L. | Métodos para proporcionar ensayos de medicina personalizada ex vivo para neoplasias hematológicas |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
| JP2013505295A (ja) | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節する化合物 |
| JP2013510178A (ja) | 2009-11-06 | 2013-03-21 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのアリールおよびヘテロアリールスルホン、組成物、および神経機能不全を治療する方法 |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| BR112012019920A2 (pt) | 2010-02-08 | 2016-04-26 | Allergan Inc | derivados de piridazina úteis como agonístas de canabinoide-2. |
| WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
| EP2595959B1 (de) * | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonylverbindungen zur modulierung des cb2-rezeptors |
| WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
| WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
| CN103534237B (zh) | 2011-05-18 | 2016-06-15 | 先正达参股股份有限公司 | 基于芳硫基乙酰胺衍生物的杀虫化合物 |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| CN109846862A (zh) | 2012-10-25 | 2019-06-07 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| WO2014079935A1 (en) | 2012-11-21 | 2014-05-30 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
| ITMI20122221A1 (it) | 2012-12-21 | 2014-06-22 | C4T S C A R L | Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende |
| EP2803668A1 (de) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| TW201609145A (zh) | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋（ｄｅｐｏｔ）之方法 |
| CN116889562A (zh) | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
| EP3597639A4 (de) * | 2017-03-15 | 2020-09-16 | Sumitomo Dainippon Pharma Co., Ltd. | Deuterierte benzimidazolverbindung und medizinische verwendung davon |
| WO2019017995A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN |
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
| KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9612434A (pt) * | 1995-12-28 | 1999-12-28 | Fujiwasa Pharmaceutical Co Ltd | Derivados de benzimidazol |
| SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| SE0302572D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| MX2007005290A (es) * | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
-
2007
- 2007-02-23 EP EP07705657A patent/EP1994011B1/de not_active Not-in-force
- 2007-02-23 CA CA2645257A patent/CA2645257C/en not_active Expired - Fee Related
- 2007-02-23 US US12/280,586 patent/US7700618B2/en not_active Expired - Fee Related
- 2007-02-23 JP JP2008557842A patent/JP2009536918A/ja not_active Ceased
- 2007-02-23 DE DE602007009807T patent/DE602007009807D1/de active Active
- 2007-02-23 AT AT07705657T patent/ATE484497T1/de not_active IP Right Cessation
- 2007-02-23 WO PCT/IB2007/000474 patent/WO2007102059A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP1994011A1 (de) | 2008-11-26 |
| US20090137584A1 (en) | 2009-05-28 |
| EP1994011B1 (de) | 2010-10-13 |
| US7700618B2 (en) | 2010-04-20 |
| CA2645257C (en) | 2011-11-01 |
| WO2007102059A1 (en) | 2007-09-13 |
| DE602007009807D1 (de) | 2010-11-25 |
| JP2009536918A (ja) | 2009-10-22 |
| CA2645257A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE484497T1 (de) | Sulfonylbenzimidazolderivate | |
| TW200621724A (en) | Sulfonyl benzimidazole derivatives | |
| ATE493391T1 (de) | Benzimidazolonderivate als cb2-rezeptor-liganden | |
| WO2008032164A3 (en) | Benzimidazolone derivatives | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| NO20091489L (no) | Tiazolpyrazolopyridiner som CRF1 reseptorantagonister | |
| CY1117974T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
| PE20091225A1 (es) | Derivados de quinolina como antagonistas del receptor p2x7 | |
| MX2015001500A (es) | Compuestos antidiabeticos triciclicos. | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| GT200600082A (es) | Derivados del 2-(1,5-difenil-1h-pirazol-3-il)-1,3,4-oxadiazol, su preparacion y su aplicacion en terapeutica | |
| WO2009069032A3 (en) | Novel glucocorticoid receptor agonists | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| US20150376129A1 (en) | Substituted benzamides with activity towards ep4 receptors | |
| WO2010018112A3 (en) | Monoaryl aminotetralines | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| ATE530176T1 (de) | Verwendung von kaffeesäure und ihren derivaten gegen krebs | |
| CY1112500T1 (el) | Νεες ετεροκυκλικες ενωσεις ως ανταγωνιστες μglu5 | |
| EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
| CA2967857A1 (en) | 1,9-diazaspiro undecane compounds having multimodal activity against pain | |
| RU2016133720A (ru) | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека | |
| EA201290532A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5 | |
| WO2015028976A3 (en) | Compounds and methods for the treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |